IPF patients treated with OFEV® (nintedanib) versus placebo were twice as likely to have improved or stable lung function1
Additionally, a pooled analysis from the TOMORROW™ and INPULSIS® trials assessed the incidence rates for major adverse cardiovascular events (MACE) among patients treated with OFEV® and p......

